…name (Mavenclad). In June 2017, Mavenclad received a positive nod from the Committee for Medicinal Products for Human Use (CHMP), and forwarded its recommendation for approval to the EMA. A decision is expected in September. Cladribine tablets is currently in review with Health Canada, and is expected to become available for the treatment of RRMS in the next few months. Addressing safety concerns The chief safety concern of regulators in 2009 was…

…dose of ocrelizumab. Ocrelizumab was excreted in breast milk in animal studies and women are advised not to breastfeed during treatment. Click on the link to download the Canadian Product Monograph: www.rochecanada.com//content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Ocrevus/OCREVUS_PM_E.pdf…

…vailable. In the group who stopped treatment and never restarted, the most common DMTs at the time of quitting were Copaxone, Rebif, Avonex, Betaseron and Tecfidera. The treatments least commonly associated with permanent discontinuation were Tysabri and Aubagio. The survey also questioned MS patients about their use of other therapies. Overall, 34.1% said they took alternative/complementary therapies. A total of 64.9% said they take vitamin/miner…